Stocktoria
biote Corp. BTMD
Nasdaq · stock · Medicinal Chemicals & Botanical Products · website · IPO 2021-03-02
biote Corp. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $192.2M | $197.2M | $185.4M | $165.0M | $139.4M |
| SG&A expense | $101.8M | $107.5M | $98.8M | $171.1M | $49.1M |
| Operating income | $35.6M | $31.6M | $28.7M | -$60.7M | $34.6M |
| Income tax | $6.0M | $970,000 | $2.7M | $388,000 | $286,000 |
| Net income | $27.0M | $3.2M | $3.3M | -$969,000 | $11.1M |
| EPS (diluted) | $0.74 | $0.09 | $0.13 | $-0.12 | — |
| Operating cash flow | $35.2M | $45.2M | $26.9M | -$9.2M | $33.7M |
| Free cash flow | $30.2M | $38.8M | $26.5M | -$9.5M | $32.3M |
| Cash & equivalents | $24.1M | $39.3M | $89.0M | $79.2M | $130,359 |
| Inventory | $19.1M | $14.8M | $17.3M | $11.2M | $9.6M |
| Total assets | $107.6M | $122.4M | $155.3M | $111.6M | $54.3M |
| Total liabilities | $158.0M | $224.6M | $191.8M | $169.9M | $50.2M |
| Shareholders' equity | -$58.5M | -$105.9M | -$36.5M | -$58.3M | $4.1M |
Growth · year-over-year · Revenue CAGR 8.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | -2.5% | +6.4% | +12.4% | +18.3% | — |
| Net income growth | +756.7% | -4.8% | — | -108.7% | — |
| EPS growth | +722.2% | -30.8% | — | — | — |
| Free cash flow growth | -22.2% | +46.3% | — | -129.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.